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LEVOCABASTINE is a highly potent and selective HI-
receptor antagonist specifically developed for
topical administration by ocular and nasal routes.
The clinical effects of levocabastine occur rapidly
and are predominantly due to local anti-
histaminic effects at the site of application. Clini-
cally, levocabastine is well tolerated with an
adverse effect profile comparable with that of
sodium cromoglycate and placebo. As might be
expected from the route of drug administration,
local irritation is the most frequent adverse event
seen with levocabastine eye drops and nasal
spray with an incidence comparable with that in
placebo-treated controls. Intranasal application
of levocabastine has been shown to have no
adverse effect on ciliary activity both in vitro and
in vivo, while ocular administration has not been
shown to have any significant or consistent
adverse effect in both animal and human studies.
At therapeutic doses, levocabastine appears to be
devoid of significant systemic activity producing
no apparent effects on cardiovascular, psycho-
motor and cognitive function. Since levocabastine
undergoes little hepatic metabolism, and only
low plasma levels of the drug are attained follow-
ing topical administration, drug interactions are
unlikely.
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Introduction
Histamine Hi-receptor antagonists are widely
considered to be a primary treatment option for
the clinical management of allergic rhino-
conjunctivitis. However, although the clinical effi-
cacy of second generation non-sedating oral
antihistamines is well documented, topical
therapy may be preferable due to the reduced
potential for systemic adverse effects.
Topical therapy available for the treatment of
allergic conjunctivitis includes corticosteroids,
sodium cromoglycate and vasoconstrictors, either
administered alone or in combination with an
Hi-receptor antagonist. Intranasal corticosteroids
provide effective relief from nasal symptoms and
are generally well tolerated. However, ocular
steroid administration should generally be
avoided due to an associated risk of 81aucoma,
cataracts and opportunistic infections. Sodium
cromoglycate is a well tolerated agent for the
prophylaxis of allergic rhinoconjunctivitis and is
suitable for both intranasal and ocular adminis-
tration. The therapeutic efficacy of this drug is
highly variable and maintenance therapy through-
out the period of allergen exposure is essential.
Topical vasoconstrictors provide effective relief
only for nasal obstructive symptoms and are only
suitable for short-term therapy due to the poten-
tial for rebound vasodilatation during prolonged
use.3,4
Until recently, topical antihistamines have not
been sufficiently potent to enable single agent
therapy, necessitating co-administration of a vaso-
constrictor. While reports suggest that such com-
binations may be more effective than
Vasoconstrictor monotherapy,
5 they are not sui-
table for long-term use due to the adverse reac-
tions associated with topical vasoconstrictors.
Levocabastine
Levocabastine is an extremely potent and
highly selective Hi-receptor antagonist which has
been specifically developed for topical ocular
and nasal administration. Levocabastine is the
most potent antihistamine available to date
expressing antihistaminic activity at doses lower
than 0.002 mg/kg, making it some 15 000 times
more potent than chlorpheniramine.
7 In addition,
animal studies have shown that this agent has a
very ,high specificity for HI-receptors being
devoid of anticholinergic, antiserotoninergic or
antidopaminergic activity at concentrations
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considerably greater than effective antihistaminic
doses. This suggests that adverse reactions result-
ing from a lack of receptor specificity are un-
likely. Levocabastine is a potent inhibitor of
experimentally induced rhinocon-junctivitis pro-
viding effective relief from symptoms within
minutes of instillation,
8-1 with comparative clin-
ical trials demonstrating that this agent is at least
as effective as oral antihistamines in patients with
clinical disease.14-17
Pharmacokinetic analysis suggests that the
potential for systemic adverse effects is very low.
Levocabastine is incompletely absorbed after
intranasal and ocular administration with systemic
availability typically ranging from 30-60% for the
eye drops and 60-80% for the nasal spray.s
Moreover, as the amount of drug applied topi-
cally is small, the plasma concentration of levoca-
bastine attained via these routes of administration
is extremely low with Cmax values in the range of
0.2-0.29 mg/1 for levocabastine eye drops and
1.4-2.2 mg/1 for the nasal spray. Detailed phar-
macokinetic-pharmacodynamic modelling con-
firms those findings, indicating that the clinical
benefits seen with this agent are predominantly
due to local antihistaminic effects at the site of
application.
9 Coupled with the fact that levoca-
bastine is subject to minimal hepatic metabolism,
this suggests that the potential for systemic
adverse reactions is minimal.
The present review aims to summarize the
data available to date concerning the tolerability
and safety of levocabastine eye drops and nasal
spray with particular reference to implications for
the clinical management of patients with allergic
rhinoconjunctivitis.
Tolerability
The tolerability of levocabastine eye drops and
nasal spray has been extensively evaluated in
clinical trials. The available data suggests that
topical levocabastine is well tolerated with an
adverse effect profile comparable with that of
sodium cromoglycate or placebo. Analysis of data
from a total of 1628 patients treated with levoca-
bastine eye drops reveals that local irritation is
the most frequently reported adverse event fol-
lowing ocular administration with an incidence of
14%. Of 1758 patients who have received levoca-
bastine nasal spray, headache (4%), nasal irrita-
tion (3%), somnolence (3%) and fatigue (2%)
have been reported. The overall incidence of
adverse experiences on levocabastine eye drops
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FIG. 1. Incidence of adverse experiences with levocabastine nasal spray and eye drops compared with sodium cromoglycate and
placebo.
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is 24%. In separate studies the incidence has wide range of objective ophthalmological tests
been comparable for levocabastine and placebo including slit lamp evaluation, tonometry, fluor-
(27 versus 31%), levocabastine and cromoglycate escein and rose bengal staining, ophthalmoscopy
(36 versus 31%) and levocabastine and terfena- and determination of intraocular pressure, visual
dine (40 versus 41%). Figure 1 shows the toler- acuity and visual fields. These studies have failed
ability of levocabastine compared with sodium to reveal any significant or consistent adverse
cromoglycate and placebo, effects attributable to the topical antihistamine at
In addition, no clinically significant changes in doses of up to 4 times daily and treatment dura-
biochemical or haematological parameters have tions of up to 8 weeks.2
been reported during treatment with this topical As many traditional antihistamines have been
antihistamine in clinical trials that have per- associated with anticholinergic activity, which
formed routine laboratory tests to date. Sig- may be expected to influence accommodative
nificandy, the type and frequency of adverse capacity, the effects of ocular administration of
experiences appears to be unrelated to the levocabastine on accommodation have been
number of daily applications. Moreover, adverse investigated in healthy volunteers and in patients
effects do not appear to be increased by con- with glaucoma.
24 Administration of a single dose
comitant use of the eye drops and nasal spray of levocabastine (0.5 mg/ml)was found to have
compared with use of either formulation alone, no effect on accommodative capacity in healthy
Drug tolerability is a key factor determining volunteers. Similarly, accommodative capacity and
choice of therapy in children. Importantly, a intraocular pressure were unchanged in patients
study involving 53 children aged between 6 and with glaucoma during twice daily treatment with
15 years reported that levocabastine nasal spray ocular levocabastine over a period of 2 weeks.
and eye drops are well tolerated in this patient These findings are in keeping with the highly
population with type and incidence of adverse selective pharmacological profile of the drug.
reactions similar to those occurring in sodium-
cromoglycate-treated children.
2 Psychomotor effects of levocabastine: Many tradi-
tional H-receptor antagonists cross the blood-
Local tolerance.. It is well documented that intra- brain barrier producing unwanted central
nasal administration of certain drugs and addi- nervous system effects. Increased daytime som-
fives, in particular decongestants, can influence nolence and reduced alertness, are frequent
ciliary activity of the upper airways.
2 The influ- adverse reactions particularly encountered with
ence of levocabastine on ciliary beat frequency many first-generation oral antihistamines.
and mucociliary clearance has been evaluated in Pharmacokinetic studies indicate that sedative
vitro using human adenoid tissue and in vivo effects would be extremely unlikely in patients
following single and multiple dose administration receiving intranasal or ocular levocabastine due
in healthy human volunteers.
22 Levocabastine was to the low plasma concentrations of the drug
seen to have only a small, clinically insignificant obtained by these routes of administration.
effect on ciliary beat frequency in human Specific studies of psychomotor and cognitive
adenoid tissue. No significant effects on ciliary function following topical administration of levo-
function were observed following single- and cabastine support these findings. Objective
multiple-dose administration in healthy volun- assessment of psychomotor performance and
teers, subjective assessment of sedation have failed to
Ocular tolerance of levocabastine has been reveal any central nervous system effects in
evaluated extensively. Animal studies have failed healthy volunteers treated with levocabastine eye
to reveal any adverse effects resulting from drops (0.5 mg/ml, two drops in each eye, four
topical administration of levocabastine eye drops, times daily) over a period of 1 week.25 Potential
In an eye irritation study in rabbits, application of central nervous system effects of levocabastine
levocabastine eye drops four to eight times daily have also been investigated following single- and
for 4 weeks did not produce ocular changes, and multiple-dose administration of levocabastine eye
in another study, normal intraocular pressure was drops and nasal spray, and compared with those
found to be maintained in rabbits following of oral triprolidine. Performance was assessed
application of levocabastine. Levocabastine did following medication by a battery of cognitive
not induce dermal sensitization when tested in and psychomotor tests considered as reliable
guinea-pigs using the Magnusson maximization measures of the sedative effects of psychoactive
technique.
18 drugs. In contrast to the significant sedative
The local tolerance of levocabastine eye drops effects of triprolidine, topical administration of
has also been extensively evaluated in volunteers levocabastine eye drops and nasal spray at doses
and atopic patients during clinical trials using a up to 2.0 mg/ml, a dose level four times greater
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FIG. 2. The effects of levocabastine (a) nasal spray two puffs/nostril and eye drops one drop/eye q.i.d, for 7 days and (b) 3 mg orally
for 3 days on the QTc-interval in man.
than normal therapeutic dosages, had no demon-
strable effect on central nervous system function
in healthy volunteers.2
Potential pharmacokinetic and psychomotor
interactions between levocabastine nasal spray
and alcohol or diazepam have also been investi-
gated in healthy volunteers. No evidence of sig-
nifican psychomotor interactions between
levocabastine and either ethanol or diazepam are
apparent.
Cardiovascular effects of levocabastine: Possible
cardiovascular effects of levocabastine have been
assessed in vitro on isolated Purkinje fibres of
dogs and in vivo in animal studies and in human
volunteers following oral, ocular and nasal
administration. In vitro studies on isolated Pur-
kinje fibres revealed no effect of levocabastine
on action potential amplitude and action poten-
tial duration at 50% and 90% repolarization at
doses of up to 2.5 mg/1. Similarly, oral adminis-
tration of doses of up to 0.16 mg/kg have
revealed no significant effect on key cardiovas-
cular parameters in dogs.
More relevantly, levocabastine does not appear
to produce significant ECG effects in man.
Several studies in healthy volunteers (Fig. 2) have
revealed no significant effects on QT- or QTc-
intervals after treatment with levocabastine in
single or repeated doses, even when the eye
drops and the nasal spray are used in combina-
tion four times daily (1.2 mg/day) or after
administration of oral levocabastine 3 mg daily
(for 3 days).27
Drug interactions: As levocabastine plasma con-
centrations are extremely low following topical
administration and hepatic metabolism is negli-
gible, clinically significant drug interactions are
unlikely. But since binding studies have revealed
that levocabastine binds to plasma proteins, par-
ticularly albumin, the potential for drug interac-
tions involving binding site displacement exists.
However, in vitro analysis of potential pharmaco-
kinetic drug interactions have identified levoca-
bastine does not alter the plasma protein binding
of imipramine, propranolol, diphenylhydantoin,
diazepam, cimetidine, indomethacin or ketocona-
zole although slight increases in the proportion
of unbound levocabastine can be identified with
drugs which are highly protein-bound such as
sulphamethazine (4.5%), tolbutamide (6%) and
warfarin (8.19/o). Although such changes are
minor they should be recognized. Obviously this
interaction is of no clinical relevance for levoca-
bastine as its plasma protein binding is only
55%.
18
Conclusion
Extensive clinical investigations have shown
levocabastine eye drops and nasal spray to be
highly effective for the treatment of allergic rhi-
noconjunctivitis. Levocabastine eye drops and
nasal spray are well tolerated with an adverse-
effect profile comparable with that of sodium
cromoglycate and placebo. Local irritation follow-
ing administration is the most common adverse
reaction reported in levocabastine-treated
patients to date with an incidence similar to that
seen in placebo- or cromoglycate-treated con-
trois. Importantly, the potential for systemic
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adverse effects is negligible. As would be expec-
ted from its pharmacological profile, levocabas-
tine is devoid of significant systemic activity
having no apparent effects on cardiovascular
function, psychomotor performance, cognitive
function and minimal interaction potential.
Coupled with its well documented therapeutic
efficacy, these findings indicate that topical levo-
cabastine is an attractive therapeutic option for
the treatment of allergic conjunctivitis.
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